Optimizing HFrEF Patients Using BaroStim and CardioMems

Summary

The goal of this study is to utilize CardioMems (measurement of pulmonary artery diastolic pressure) to assess BaroStim. At the time of CardioMems insertion, patients will be screened for candidacy to receive a BaroStim device. Patients will be followed for 3 months after the CardioMems insertion before undergoing insertion of a Barostim. Patients who have undergone a CardioMems, will be eligible for enrollment after 3 months of medication management and optimization. Patients will be followed for 1 year after insertion of Barostim.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Heart Failure NYHA Class III

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2/3

Ages

18 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Northwell Health

Last updated on ClinicalTrials.gov

February 10, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites